MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from public
offering, net of...
$187,948K
Proceeds from exercise of
common stock options
$2,415K
Net cash provided by
financing activities
$189,592K
Canceled cashflow
$771K
Net increase in cash
and cash...
$25,938K
Canceled cashflow
$163,654K
Payments related to
offering costs
$771K
Maturities of marketable
securities
$267,872K
Call redemptions of
marketable securities
$8,500K
Stock-based compensation
expense
$8,677K
Accrued expenses
$6,796K
Operating lease liability
$425K
Depreciation expense
$248K
Non cash operating
lease expense
$133K
Other assets
-$8K
Net cash used in
investing activities
-$83,705K
Net cash used in
operating activities
-$79,949K
Canceled cashflow
$276,372K
Canceled cashflow
$16,287K
Purchases of marketable
securities
$358,148K
Net loss
-$86,971K
Purchases of property and
equipment
$1,929K
Accretion and
amortization of marketable...
$3,611K
Prepaid expenses and
other current assets
$2,697K
Accounts payable
-$2,456K
Operating lease
right-of-use asset
$501K
Back
Back
Cash Flow
source: myfinsight.com
MBX Biosciences, Inc. (MBX)
MBX Biosciences, Inc. (MBX)